{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:44:41Z","timestamp":1786981481515,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mycopathologia"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Numbers of infections with azole-resistant\n                    <jats:italic>Aspergillus fumigatus<\/jats:italic>\n                    (ARAf) were rising in the last decades. We assessed ARAf susceptibility trends towards five antifungal agents (amphotericin B (AMB), itraconazole (ITR), voriconazole (VCZ), olorofim (OLO) and manogepix (MGX)) over twelve\u00a0years in a German Excellence Center for Medical Mycology (ECMM). In addition, underlying mutations were studied and correlated with trends in minimum inhibitory concentration (MIC). Broth microdilution (BMD) was performed following EUCAST guidelines for 143 clinical ARAf isolates collected between the years 2011 and 2022 in a West German tertiary care centre. BMD was carried out for all antifungal agents in the following concentration ranges: 0.016\u20138\u00a0mg\/L for AMB, ITR and VCZ as well as 0.001\u20130.5\u00a0mg\/L for OLO and 0.004\u20132\u00a0mg\/L for MGX. Molecular assays on mutations associated with antifungal resistance were performed for all 143 isolates (AsperGenius\u00ae 1.0, Pathonostics, Maastricht, The Netherlands) and for a total of ten non TR\n                    <jats:sub>34<\/jats:sub>\n                    \/L98H and TR\n                    <jats:sub>46<\/jats:sub>\n                    \/Y121F\/T289A mutated ARAf isolates additional\n                    <jats:italic>cyp51A<\/jats:italic>\n                    sequencing was carried out. For all isolates, microdilution revealed a MIC\n                    <jats:sub>50<\/jats:sub>\n                    of\u2009&gt;\u20098\u00a0mg\/L for ITR, 4\u00a0mg\/L for VCZ, 0.03\u00a0mg\/L for OLO, 0.016\u00a0mg\/L for MGX, and 0.5\u00a0mg\/L for AMB. Considering EUCAST breakpoints, 97.9% of the strains (n\u2009=\u2009140) were resistant to VCZ, 1.4% (n\u2009=\u20092) towards AMB and 92.3% towards ITR (n\u2009=\u2009132). Molecular assays revealed 123 (86%) isolates with the azole resistance underlying mutation TR\n                    <jats:sub>34<\/jats:sub>\n                    \/L98H, 10 (7%) with a TR\n                    <jats:sub>46<\/jats:sub>\n                    \/Y121F\/T289A mutation and 10 (7%) with other\n                    <jats:italic>cyp51A<\/jats:italic>\n                    mutations. A comparison of triazole MICs of isolates collected from 2011 to 2019 with the MICs of isolates collected between 2020 and 2022 revealed no significant differences for itraconazole (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.543) and for voriconazole (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.148),with a trend of increased geometric mean for ITR and VCZ MICs over time. MICs for OLO and MGX did not significantly differ between isolates with the distinct azole-resistance underlying mutations. Before 2016, the azole resistance underlying mutations were mainly TR\n                    <jats:sub>34<\/jats:sub>\n                    \/L98H, but the portion of isolates with TR\n                    <jats:sub>46<\/jats:sub>\n                    \/Y121F\/T289A and other\n                    <jats:italic>Cyp51A<\/jats:italic>\n                    mutated isolates increased afterwards. We showed almost stable MICs for ITR and VCZ over twelve years in ARAf isolates from West Germany while occurring azole resistance underlying mutations varied with an increase in the proportion of TR\n                    <jats:sub>46<\/jats:sub>\n                    \/Y121F\/T289A and other\n                    <jats:italic>Cyp51A<\/jats:italic>\n                    mutations after 2016.\n                  <\/jats:p>","DOI":"10.1007\/s11046-025-00941-x","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T22:37:28Z","timestamp":1743892648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Trends of Azole-Resistant Aspergillus Fumigatus Susceptibility Over 12 Years from a German ECMM Excellence Center"],"prefix":"10.1007","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5601-2444","authenticated-orcid":false,"given":"Hedda Luise","family":"Verhasselt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Thissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Scharmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Dittmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter-Michael","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Steinmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Kirchhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"issue":"10","key":"941_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186422","volume":"12","author":"KS Sun","year":"2017","unstructured":"Sun KS, Tsai CF, Chen SC, Huang WC. Clinical outcome and prognostic factors associated with invasive pulmonary aspergillosis: an 11-year follow-up report from Taiwan. PLoS ONE. 2017;12(10): e0186422.","journal-title":"PLoS ONE"},{"issue":"10","key":"941_CR2","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/cid\/ciw563","volume":"63","author":"M Legrand","year":"2016","unstructured":"Legrand M, Gits-Muselli M, Boutin L, Garcia-Hermoso D, Maurel V, Soussi S, et al. Detection of circulating mucorales DNA in critically Ill burn patients: preliminary report of a screening strategy for early diagnosis and treatment. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2016;63(10):1312\u20137.","journal-title":"Clin Infect Dis: Off Publ Infect Dis Soc Am"},{"issue":"2","key":"941_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.idc.2021.03.008","volume":"35","author":"J Cadena","year":"2021","unstructured":"Cadena J, Thompson GR 3rd, Patterson TF. Aspergillosis: epidemiology, diagnosis, and treatment. Infect Dis Clin North Am. 2021;35(2):415\u201334.","journal-title":"Infect Dis Clin North Am"},{"issue":"4","key":"941_CR4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jac\/44.4.553","volume":"44","author":"E Dannaoui","year":"1999","unstructured":"Dannaoui E, Persat F, Monier MF, Borel E, Piens MA, Picot S. In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole. J Antimicrob Chemother. 1999;44(4):553\u20135.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"941_CR5","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1128\/AAC.41.6.1364","volume":"41","author":"DW Denning","year":"1997","unstructured":"Denning DW, Venkateswarlu K, Oakley KL, Anderson MJ, Manning NJ, Stevens DA, Warnock DW, Kelly SL. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 1997;41(6):1364\u20138. https:\/\/doi.org\/10.1128\/AAC.41.6.1364.","journal-title":"Antimicrob Agents Chemother"},{"key":"941_CR6","unstructured":"WHO. WHO fungal priority pathogens list to guide research, development and public health action. 2022."},{"issue":"1","key":"941_CR7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3201\/eid2501.171925","volume":"25","author":"JB Buil","year":"2019","unstructured":"Buil JB, Snelders E, Denardi LB, Melchers WJG, Verweij PE. Trends in Azole Resistance in Aspergillus fumigatus, the Netherlands, 1994\u20132016. Emerg Infect Dis. 2019;25(1):176\u20138. https:\/\/doi.org\/10.3201\/eid2501.171925.","journal-title":"Emerg Infect Dis"},{"key":"941_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.613774","volume":"10","author":"H Guegan","year":"2020","unstructured":"Guegan H, Prat E, Robert-Gangneux F, Gangneux JP. Azole Resistance in Aspergillus fumigatus: a five-year follow up experience in a tertiary hospital with a special focus on cystic fibrosis. Front Cell Infect Microbiol. 2020;10: 613774.","journal-title":"Front Cell Infect Microbiol"},{"issue":"6","key":"941_CR9","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1128\/AAC.01092-06","volume":"51","author":"E Mellado","year":"2007","unstructured":"Mellado E, Garcia-Effron G, Alc\u00e1zar-Fuoli L, Melchers WJ, Verweij PE, Cuenca-Estrella M, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother. 2007;51(6):1897\u2013904.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"941_CR10","doi-asserted-by":"publisher","first-page":"e103113","DOI":"10.1371\/journal.pone.0103113","volume":"9","author":"B Spiess","year":"2014","unstructured":"Spiess B, Postina P, Reinwald M, Cornely OA, Hamprecht A, Hoenigl M, et al. Incidence of Cyp51 a key mutations in Aspergillus fumigatus\u2014A study on primary clinical samples of immunocompromised patients in the period of 1995\u20132013. PLoS ONE. 2014;9(7):e103113. https:\/\/doi.org\/10.1371\/journal.pone.0103113.","journal-title":"PLoS ONE"},{"issue":"3","key":"941_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3390\/jof4030098","volume":"4","author":"JD Jenks","year":"2018","unstructured":"Jenks JD, Hoenigl M. Treatment of Aspergillosis. J Fungi. 2018;4(3):98. https:\/\/doi.org\/10.3390\/jof4030098.","journal-title":"J Fungi"},{"key":"941_CR12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/myc.12759","volume":"61","author":"F Reichert-Lima","year":"2018","unstructured":"Reichert-Lima F, Lyra L, Pontes L, Moretti ML, Pham CD, Lockhart SR, et al. Surveillance for Azoles Resistance in Aspergillus spp. highlights a high number of amphotericin B-resistant isolates. Mycoses. 2018;61:360\u20135.","journal-title":"Mycoses"},{"issue":"4","key":"941_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3390\/jof6040239","volume":"6","author":"KJ Shaw","year":"2020","unstructured":"Shaw KJ, Ibrahim AS. Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections. J Fungi. 2020;6(4):239. https:\/\/doi.org\/10.3390\/jof6040239.","journal-title":"J Fungi"},{"key":"941_CR14","unstructured":"F2G Receives Complete Response Letter from FDA for New Drug Application for Olorofim for The Treatment of Invasive Fungal Infections; Plans Resubmission With Additional Data and Analyses [press release]. https:\/\/www.f2g.com\/press_releases: F2G2023."},{"issue":"3","key":"941_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/nmi2.44","volume":"2","author":"J Steinmann","year":"2014","unstructured":"Steinmann J, Giraud S, Schmidt D, Sedlacek L, Hamprecht A, Houbraken J, et al. Validation of a novel real-time PCR for detecting Rasamsonia argillacea species complex in respiratory secretions from cystic fibrosis patients. New Microb New Infect. 2014;2(3):72\u20138.","journal-title":"New Microb New Infect"},{"key":"941_CR16","first-page":"4","volume":"9","author":"J Guinea","year":"2022","unstructured":"Guinea J, Meletiadis J, Arikan-Akdagli S, Muehlethaler K, Kahlmeter G, Arendrup MC. Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. EUCAST Definitive Doc EDef. 2022;9:4.","journal-title":"EUCAST Definitive Doc EDef"},{"key":"941_CR17","first-page":"31","volume":"9","author":"MC Arendrup","year":"2017","unstructured":"Arendrup MC, Meletiadis J, Mouton JW, Lagrou K, Hamal P, Guinea J, et al. Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. Eucast Definitive Doc EDef. 2017;9:31.","journal-title":"Eucast Definitive Doc EDef"},{"issue":"8","key":"941_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.00730-20","volume":"64","author":"KM J\u00f8rgensen","year":"2020","unstructured":"J\u00f8rgensen KM, Astvad KMT, Arendrup MC. In vitro activity of manogepix (APX001A) and comparators against contemporary molds: MEC comparison and preliminary experience with colorimetric MIC determination. Antimicrob Agents Chemother. 2020;64(8):10\u20131128.","journal-title":"Antimicrob Agents Chemother"},{"key":"941_CR19","unstructured":"The European Committee on Antimicrobial Susceptibility T. Breakpoint tables for interpretation of MICs for antifungal agents, version 10.0, 2020. Eucast. April 2020:0\u20138."},{"issue":"1","key":"941_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/jac\/dkh507","volume":"55","author":"J Chen","year":"2005","unstructured":"Chen J, Li H, Li R, Bu D, Wan Z. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J Antimicrob Chemother. 2005;55(1):31\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"941_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/mmy\/myx015","volume":"56","author":"M Weber","year":"2018","unstructured":"Weber M, Schaer J, Walther G, Kaerger K, Steinmann J, Rath P-M, et al. FunResDB\u2014A web resource for genotypic susceptibility testing of Aspergillus fumigatus. Med Mycol. 2018;56(1):117\u201320.","journal-title":"Med Mycol"},{"key":"941_CR22","unstructured":"National Institute for Public Health and the Environment tNS. NethMap 2023: Consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands in 2022. 2023."},{"issue":"7","key":"941_CR23","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.3201\/eid2607.200088","volume":"26","author":"PPA Lestrade","year":"2020","unstructured":"Lestrade PPA, Buil JB, van der Beek MT, Kuijper EJ, van Dijk K, Kampinga GA, et al. Paradoxal trends in Azole-Resistant Aspergillus fumigatus in a national multicenter surveillance program, the Netherlands, 2013\u20132018. Emerg Infect Dis. 2020;26(7):1447\u201355.","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"941_CR24","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/mmy\/myz003","volume":"57","author":"Y Tsuchido","year":"2019","unstructured":"Tsuchido Y, Tanaka M, Nakano S, Yamamoto M, Matsumura Y, Nagao M. Prospective multicenter surveillance of clinically isolated Aspergillus species revealed azole-resistant Aspergillus fumigatus isolates with TR34\/L98H mutation in the Kyoto and Shiga regions of Japan. Med Mycol. 2019;57(8):997\u20131003.","journal-title":"Med Mycol"},{"issue":"3","key":"941_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.02059-19","volume":"64","author":"L Pontes","year":"2020","unstructured":"Pontes L, Beraquet CAG, Arai T, Pigolli GL, Lyra L, Watanabe A, et al. Aspergillus fumigatus clinical isolates carrying CYP51A with TR34\/L98H\/S297T\/F495I substitutions detected after four-year retrospective Azole Resistance screening in Brazil. Antimicrob Agents Chemother. 2020;64(3):10\u20131128.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"941_CR26","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/QCO.0000000000000005","volume":"26","author":"E Vermeulen","year":"2013","unstructured":"Vermeulen E, Lagrou K, Verweij PE. Azole resistance in Aspergillus fumigatus: a growing public health concern. Curr Opin Infect Dis. 2013;26(6):493\u2013500.","journal-title":"Curr Opin Infect Dis"},{"issue":"Suppl 1","key":"941_CR27","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.3109\/13693786.2010.508469","volume":"49","author":"SJ Howard","year":"2011","unstructured":"Howard SJ, Arendrup MC. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med Mycol. 2011;49(Suppl 1):S90\u20135.","journal-title":"Med Mycol"},{"issue":"6","key":"941_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/mbio.02213-20","volume":"11","author":"AE Barber","year":"2020","unstructured":"Barber AE, Riedel J, Sae-Ong T, Kang K, Brabetz W, Panagiotou G, et al. Effects of agricultural fungicide use on Aspergillus fumigatus abundance, antifungal susceptibility, and population structure. MBio. 2020;11(6):10\u20131128. https:\/\/doi.org\/10.1128\/mbio.02213-20.","journal-title":"MBio"},{"key":"941_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jgar.2021.04.012","volume":"26","author":"MA Pfaller","year":"2021","unstructured":"Pfaller MA, Huband MD, Flamm RK, Bien PA, Castanheira M. Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018\u20132019). J Glob Antimicrob Res. 2021;26:117\u201327.","journal-title":"J Glob Antimicrob Res"},{"key":"941_CR30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jmii.2020.09.004","volume":"54","author":"CC Lai","year":"2021","unstructured":"Lai CC, Yu WL. COVID-19 associated with pulmonary aspergillosis: a literature review. J Microbiol Immunol Infect. 2021;54:46\u201353.","journal-title":"J Microbiol Immunol Infect"},{"issue":"4","key":"941_CR31","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s12281-022-00439-9","volume":"16","author":"A Habibzadeh","year":"2022","unstructured":"Habibzadeh A, Lankarani KB, Farjam M, Akbari M, Kashani SMA, Karimimoghadam Z, et al. Prevalence of fungal drug resistance in COVID-19 Infection: a global meta-analysis. Curr Fungal Infect Rep. 2022;16(4):154\u201364.","journal-title":"Curr Fungal Infect Rep"},{"key":"941_CR32","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/myc.13430","volume":"65","author":"L Kirchhoff","year":"2022","unstructured":"Kirchhoff L, Braun LM, Schmidt D, Dittmer S, Dedy J, Herbstreit F, et al. COVID-19-associated pulmonary aspergillosis in ICU patients in a German reference centre: Phenotypic and molecular characterisation of Aspergillus fumigatus isolates. Mycoses. 2022;65:458\u201365.","journal-title":"Mycoses"},{"issue":"3","key":"941_CR33","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/jof4030103","volume":"4","author":"JB Buil","year":"2018","unstructured":"Buil JB, Hagen FA-O, Chowdhary AA-O, Verweij PE, Meis JA-O. Itraconazole, voriconazole, and posaconazole CLSI MIC distributions for wild-type and azole-resistant Aspergillus fumigatus isolates. J Fungi. 2018;4(3):103.","journal-title":"J Fungi"},{"issue":"1","key":"941_CR34","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/jac\/dku364","volume":"70","author":"J van Ingen","year":"2015","unstructured":"van Ingen J, van der Lee HA, Rijs TA, Zoll J, Leenstra T, Melchers WJ, et al. Azole, polyene and echinocandin MIC distributions for wild-type, TR34\/L98H and TR46\/Y121F\/T289A Aspergillus fumigatus isolates in the Netherlands. J Antimicrob Chemother. 2015;70(1):178\u201381.","journal-title":"J Antimicrob Chemother"},{"key":"941_CR35","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.fgb.2015.06.001","volume":"82","author":"E Snelders","year":"2015","unstructured":"Snelders E, Camps SM, Karawajczyk A, Rijs AJ, Zoll J, Verweij PE, et al. Genotype-phenotype complexity of the TR46\/Y121F\/T289A cyp51A azole resistance mechanism in Aspergillus fumigatus. Fungal Genet Biol. 2015;82:129\u201335.","journal-title":"Fungal Genet Biol"},{"issue":"11","key":"941_CR36","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.fgb.2011.08.002","volume":"48","author":"E Snelders","year":"2011","unstructured":"Snelders E, Karawajczyk A, Verhoeven RJ, Venselaar H, Schaftenaar G, Verweij PE, et al. The structure-function relationship of the Aspergillus fumigatuscyp51A L98H conversion by site-directed mutagenesis: the mechanism of L98H azole resistance. Fungal Genet Biol. 2011;48(11):1062\u201370.","journal-title":"Fungal Genet Biol"},{"issue":"1","key":"941_CR37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/jof7010022","volume":"7","author":"I Gonzalez-Jimenez","year":"2021","unstructured":"Gonzalez-Jimenez I, Lucio J, Men\u00e9ndez-Fraga MD, Mellado E, Pel\u00e1ez T. Hospital environment as a source of Azole-Resistant Aspergillus fumigatus strains with TR34\/L98H and G448S Cyp51A mutations. J Fungi (Basel). 2021;7(1):22.","journal-title":"J Fungi (Basel)"},{"issue":"5","key":"941_CR38","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/jac\/dkae038","volume":"79","author":"A Atamna","year":"2024","unstructured":"Atamna A, Yeshurun M, Shargian L, Raanani P, Kramer M, Ben Zvi H, et al. Fatal invasive pulmonary and cerebral aspergillosis due to triazole-resistant Aspergillus fumigatus with multiple CYP51A mutations. J Antimicrob Chemother. 2024;79(5):1191\u20132.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"941_CR39","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.1128\/AAC.00291-11","volume":"55","author":"M Miyazaki","year":"2011","unstructured":"Miyazaki M, Horii T, Hata K, Watanabe N-a, Nakamoto K, Tanaka K, et al. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob Agents Chemother. 2011;55(10):4652\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"941_CR40","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1128\/AAC.00366-11","volume":"55","author":"K Hata","year":"2011","unstructured":"Hata K, Horii T, Miyazaki M, Watanabe N-a, Okubo M, Sonoda J, et al. Efficacy of Oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, Aspergillosis, and fusariosis. Antimicrob Agents Chemother. 2011;55(10):4543\u201351.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"941_CR41","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1128\/AAC.05414-11","volume":"56","author":"M Castanheira","year":"2012","unstructured":"Castanheira M, Duncanson FP, Diekema DJ, Guarro J, Jones RN, Pfaller MA. Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against fusarium and scedosporium species identified using molecular methods. Antimicrob Agents Chemother. 2012;56(1):352\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"941_CR42","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1093\/jac\/dkr342","volume":"66","author":"MA Pfaller","year":"2011","unstructured":"Pfaller MA, Watanabe N, Castanheira M, Messer SA, Jones RN. Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European committee on antimicrobial susceptibility testing methods. J Antimicrob Chemother. 2011;66(11):2581\u20134.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"941_CR43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/aac.00840-19","volume":"63","author":"MA Pfaller","year":"2019","unstructured":"Pfaller MA, Huband MD, Flamm RK, Bien PA, Castanheira M. In vitro activity of APX001A (Manogepix) and comparator agents against 1,706 fungal isolates collected during an international surveillance program in 2017. Antimicrob Agents Chemother. 2019;63(8):10\u20131128. https:\/\/doi.org\/10.1128\/aac.00840-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"941_CR44","doi-asserted-by":"publisher","first-page":"106105","DOI":"10.1016\/j.ijantimicag.2020.106105","volume":"56","author":"L Kirchhoff","year":"2020","unstructured":"Kirchhoff L, Dittmer S, Buer J, Rath PM, Steinmann J. In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus. Int J Antimicrob Agents. 2020;56(3):106105.","journal-title":"Int J Antimicrob Agents"},{"key":"941_CR45","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.01527-20","volume":"65","author":"KA-O Astvad","year":"2020","unstructured":"Astvad KA-O, J\u00f8rgensen KM, Hare RA-OX, Datcu R, Arendrup MA-O. Olorofim susceptibility testing of 1,423 danish mold isolates obtained in 2018\u20132019 confirms uniform and broad-spectrum activity. Antimicrob Agents Chemother. 2020;65:10\u20131128.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"941_CR46","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.00487-18","volume":"62","author":"KM J\u00f8rgensen","year":"2018","unstructured":"J\u00f8rgensen KM, Astvad KMT, Hare RK, Arendrup MC. EUCAST determination of olorofim (F901318) susceptibility of mold species, method validation, and MICs. Antimicrob Agents Chemother. 2018;62(8):10\u20131128.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"941_CR47","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1093\/jac\/dkx177","volume":"72","author":"JB Buil","year":"2017","unstructured":"Buil JB, Rijs A, Meis JF, Birch M, Law D, Melchers WJG, et al. In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates. J Antimicrob Chemother. 2017;72(9):2548\u201352.","journal-title":"J Antimicrob Chemother"},{"key":"941_CR48","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1080\/22221751.2022.2034485","volume":"11","author":"JB Buil","year":"2022","unstructured":"Buil JB, Oliver JD, Law D, Baltussen T, Zoll J, Hokken MWJ, et al. Resistance profiling of Aspergillus fumigatus to olorofim indicates absence of intrinsic resistance and unveils the molecular mechanisms of acquired olorofim resistance. Emerg Microb Infect. 2022;11:703\u201314.","journal-title":"Emerg Microb Infect"},{"issue":"9","key":"941_CR49","doi-asserted-by":"publisher","first-page":"e00849","DOI":"10.1128\/aac.00849-22","volume":"66","author":"P Escribano","year":"2022","unstructured":"Escribano P, G\u00f3mez A, Reigadas E, Mu\u00f1oz P, Guinea J. EUCAST-obtained olorofim MICs against Aspergillus and scedosporium species and lomentospora prolificans showed high agreements between visual inspection and spectrophotometric readings. Antimicrob Agents Chemother. 2022;66(9):e00849-e922.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Mycopathologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-025-00941-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11046-025-00941-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-025-00941-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T04:16:07Z","timestamp":1744863367000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11046-025-00941-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["941"],"URL":"https:\/\/doi.org\/10.1007\/s11046-025-00941-x","relation":{},"ISSN":["0301-486X","1573-0832"],"issn-type":[{"value":"0301-486X","type":"print"},{"value":"1573-0832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study did not include patient\u2019s details and did not result in additional constraints for patients. All data were anonymously analysed without patient consent owing to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}],"article-number":"34"}}